ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Contemporary series of cytoreductive surgery and perioperative intraperitoneal chemotherapy for mucinous appendiceal tumors with peritoneal dissemination

Contemporary series of cytoreductive surgery and perioperative intraperitoneal chemotherapy for mucinous appendiceal tumors with peritoneal dissemination
Author; year N IP chemo Perioperative morbidity (%) Perioperative mortality (%) Overall survival (%)
3 years 5 years
Sugarbaker P; 1999 385 MMC + FU 27 2.7 74 63
Loungnarath R; 2005 27 MMC 44 0 80 50
Guner Z; 2005 28 Cisplatin or MMC or FU 36 7 NR 75
Moran BJ; 2006 65 MMC + FU 20 6 NR 65
Stewart J; 2006 110* MMC 38 4 59 53
Baratti D; 2008 104 MMC and cisplatin 19 1 NR 78
Chua T; 2009 106 MMC + FU 49 3 NR 75
Elias D; 2010 301 NR (n = 255) 40 4.4 85 73
Youssef H; 2011 456Δ MMC ◊ 1.6 NR 69 (57% at 10 years)
IP chemo: intraperitoneal chemotherapy; MMC: mitomycin C; FU: fluorouracil; NR: not reported.
* Included 55 disseminated peritoneal adenomucinosis (DPAM), 29 peritoneal mucinous carcinomatosis (PMCA), 18 PMCA with intermediate features, and 8 high-grade mucinous lesions.
¶ Severe (grade 3/4) morbidity.
Δ 289 patients (out of 456) had complete surgical cytoreduction; 5- and 10-year predicted survival were 87 and 74%, respectively.
◊ Grade 3 or 4 complications in 7% of patients undergoing cytoreductive surgery; among 441 patients undergoing cytoreductive surgery or major debulking, 3.6% reoperation rate for bleeding and 10% venous thromboembolism, including 2% pulmonary emboli.
Graphic 71289 Version 8.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟